GILD vs. MEDP: Gilead Sciences vs. Medpace Stock Comparison
How do Gilead Sciences (GILD) and Medpace (MEDP) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Gilead Sciences (GILD) and Medpace (MEDP) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while MEDP is classified in Life Sciences Tools & Services.
| Profile Item | GILD | MEDP |
|---|---|---|
| Name | Gilead Sciences Inc. | Medpace Holdings, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 207.00 billion USD | 18.27 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | January 22, 1992 | August 11, 2016 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GILD | MEDP |
|---|---|---|
| Total Return (1Y) | 45.69% | 13.29% |
| Total Return (3Y, Annualized) | 35.30% | 35.26% |
| Total Return (5Y, Annualized) | 25.00% | 24.49% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GILD | MEDP |
|---|---|---|
| Volatility (1Y, Annualized) | 27.57% | 44.16% |
| Beta (5Y) | 0.36 | 1.10 |
| Max Drawdown (5Y) | -26.59% | -42.87% |
| Avg. Volume (3M) | 5.98M | 258.39K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GILD | MEDP |
|---|---|---|
| Sharpe Ratio (1Y) | 1.50 | 0.20 |
| Sortino Ratio (1Y) | 2.48 | 0.26 |
Profitability
ROE (TTM)
Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-22.45%
- Max
- 109.18%
- Q3
- 6.23%
- GILD
- -22.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.88%
- MEDP
- 117.88%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Medpace (MEDP) reports 18.24%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
-12.46%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- GILD
- -12.46%
- Min
- -17.05%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.24%
- MEDP
- 18.24%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Gilead Sciences (GILD) at 42.43% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
42.43%
- Max
- 83.12%
- GILD
- 42.43%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.12%
- Max
- 83.12%
- MEDP
- 23.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GILD | MEDP |
|---|---|---|
| ROE (TTM) | -22.45% | 117.88% |
| ROA (TTM) | 13.47% | 18.71% |
| Net Margin (TTM) | -12.46% | 18.24% |
| Operating Margin (TTM) | 42.43% | 23.12% |
| Gross Margin (TTM) | 79.95% | 72.24% |
Growth
Revenue Growth
Both Gilead Sciences (GILD) at 2.39% and Medpace (MEDP) at 19.97% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Medpace (MEDP) at 20.98%, which is closer to a typical peer reading.
Growth Metrics
| Metric | GILD | MEDP |
|---|---|---|
| Revenue Growth (YoY) | 2.39% | 19.97% |
| Revenue Growth (3Y CAGR) | 2.57% | 20.12% |
| EPS Growth (YoY) | 1,684.21% | 20.98% |
| EPS Growth (3Y CAGR) | 23.04% | 28.04% |
Financial Strength
Current Ratio (MRQ)
Both Gilead Sciences (GILD) at 1.38 and Medpace (MEDP) at 0.83 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GILD
- 1.38
- Min
- 0.10
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MEDP
- 0.83
- Min
- 0.10
Debt / Equity (MRQ)
Medpace (MEDP) at 0.29 is near its industry mid-range for debt-to-equity ratio, while Gilead Sciences (GILD) at 2.02 sits above its benchmark range, pointing to a heavier debt load relative to equity.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.02
- GILD
- 2.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.29
- Max
- 1.42
- Q3
- 0.65
- MEDP
- 0.29
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GILD | MEDP |
|---|---|---|
| Current Ratio (MRQ) | 1.38 | 0.83 |
| Debt / Equity (MRQ) | 2.02 | 0.29 |
| Net Debt / EBITDA | 1.25 | -0.84 |
Dividends
Dividend Yield (TTM)
Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.94%
- GILD
- 1.94%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.46%
- GILD
- 43.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MEDP
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GILD | MEDP |
|---|---|---|
| Dividend Yield (TTM) | 1.94% | 0.00% |
| Dividend Payout Ratio (TTM) | 43.46% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- GILD
- --
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.26
- Max
- 85.34
- Q3
- 43.46
- MEDP
- 36.26
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- GILD
- 6.68
- Q1
- 3.01
- Min
- 0.01
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.44
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MEDP
- 6.44
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Measured against book value, both Gilead Sciences (GILD) at 15.88 and Medpace (MEDP) at 31.23 look expensive — each P/B ratio sits above its industry’s benchmark range.
GILD
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.88
- GILD
- 15.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MEDP
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.23
- MEDP
- 31.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GILD | MEDP |
|---|---|---|
| P/E Ratio (TTM) | -- | 36.26 |
| P/S Ratio (TTM) | 6.68 | 6.44 |
| P/B Ratio (MRQ) | 15.88 | 31.23 |
| Free Cash Flow Yield (TTM) | 5.16% | 2.72% |